Blog
RSS FeedPosted by Michael Wonder on 17 Oct 2022
Can state prescription drug affordability boards address high cost drug prices?
11 October 2022 - State law makers, like their federal counterparts, are focused on addressing the high and growing cost of ...
Posted by Michael Wonder on 17 Oct 2022
ICER releases draft evidence report on treatments for multiple sclerosis
17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 13 Oct 2022
HARmonized protocol template to enhance reproducibility of hypothesis evaluating real world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force
12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...
Posted by Michael Wonder on 11 Oct 2022
New generation of weight loss medications offer promise — but at a price
11 October 2022 - Excitement is building about a new generation of drugs that tout the ability to help adults ...
Posted by Michael Wonder on 11 Oct 2022
ICER releases draft evidence report on treatment for vasomotor symptoms associated with menopause
11 October 2022 - Registration now open for October 19 “Early Insights” webinar. ...
Posted by Michael Wonder on 05 Oct 2022
ICER to assess treatments for non-alcoholic steatohepatitis
5 October 2022 - Report will be subject of Midwest CEPAC meeting in April 2023; Draft Scoping Document open to ...
Posted by Michael Wonder on 04 Oct 2022
Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement
4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...
Posted by Michael Wonder on 13 Sep 2022
ICER releases draft evidence report on gene therapies for haemophilia A and B
13 September 2022 - Registration now open for 20 September “Early Insights” webinar. ...
Posted by Michael Wonder on 13 Sep 2022
ICER publishes final evidence report and policy recommendations on treatments for amyotrophic lateral sclerosis
13 September 2022 - Majority of independent appraisal committee voted that evidence is adequate to demonstrate that both AMX0035 and oral ...
Posted by Michael Wonder on 31 Aug 2022
ICER publishes evidence report on treatments for obesity management
31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...
Posted by Michael Wonder on 04 Aug 2022
ICER publishes evidence report on treatments for amyotrophic lateral sclerosis
4 August 2022 - Given current data, AMX0035 is comparable or better to standard of care; AMX0035 would achieve common thresholds ...
Posted by Michael Wonder on 19 Jul 2022
ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
Posted by Michael Wonder on 13 Jul 2022
ICER releases draft evidence report on treatments for obesity management
13 July 2022 - Registration now open for 26 July “Early Insights” webinar. ...
Posted by Michael Wonder on 11 Jul 2022
ICER launches initiative to evaluate and advance health technology assessment methods that support health equity
11 July 2022 - Funding from Commonwealth Fund supports a broad based initiative exploring potential changes in all health technology assessment ...
Posted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...